Loading...

ENVB ENVERIC BIOSCIENCES INC Investments/Divestments 8-K Filing

NVRC

NVB

ENVERIC BIOSCIENCES INC

(ENVB)

2023 8-K

Show Summary

Summary

Elections of Directors

Financial Statements

Accountant Change

Financial Results

Nasdaq Compliance

Investor Presentation

Public Offering

Stock Split Update

Stock Split Announcement

Investor Presentation

Nasdaq Delisting Notice

Q3 Financial Results

Out-Licensing Agreement

Investor Presentation

Q2 Financial Results

Agreement with Aries Scienc...

Annual Meeting Voting Results

Financial Results Announcement

Shareholder Director Nomina...

Financial Results Announcement

Agreement for Stock Issuance

Reduction in Force

Press Release Update

Warrant Exercise Inducement...

Drug Candidate Selection

GLP Safety and Toxicology P...

Announcement of Compound Se...

Patent Allowance

Earnings Reports

Purchase Agreement and Regi...

Amendment to Incentive Plan

Patent Approval

Patent Issuance

Conference Presentation

Equity Distribution Agreement

Regulation FD Disclosure

Earnings Report

New Product Launches

Investor Conferences

Patent Allowance

Termination of Employment C...

Submission of Manuscript fo...

Participation in Convention

USPTO Notice of Allowance

Participation in Conference

Financial Results Announcement

External Links:

Enveric Biosciences, Inc. announced the selection of EB-003 as its lead drug candidate and plans to initiate preclinical development in early 2024 for a first-in-human clinical trial.

AI Assistant

ENVERIC BIOSCIENCES INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.